DNA X Inc

DNA X Inc (SONM) Stock Analysis

$3.079

-0.107 (-3.47%)At close

Loading chart…
High
3.245
Open
3.245
VWAP
3.13
Volume
2.81K
Mkt Cap
47.89M
Low
3.079
Amount
8.81K
EV/EBITDA, TTM
0.00

DNA X, Inc., formerly Sonim Technologies, Inc., is a digital asset management platform, building on the digital asset trading platform. The Company operates an artificial intelligence (AI) and crypto trading platform designed to automate trading strategies using machine learning technologies. It provides a digital asset trading platform that allows users to trade or swap cryptocurrencies for other cryptocurrencies or cash equivalent currencies. The Company’s DNA X trading website enables users to implement strategies to take advantage of fluctuations in relative values of cryptocurrency pairs. The platform allows users to set up automated trading strategies, monitor other traders’ trading strategies in real time, and simulate trades. The Company generates revenue from trading commissions based on the value of trades executed on its platform. It serves individual investors from around the world and supports its operations through subsidiaries located in China, Germany, and Hong Kong.

AI analysis of DNA X Inc (SONM)

Sell

Sonim Technologies Inc (SONM) is not a good buy right now due to its significant financial losses and poor performance indicators. The current price is $3.08, and the stock has a 1-year change of -72.92%, indicating a substantial decline in value. Additionally, the RSI is at 30.545, suggesting that the stock is oversold, but this does not guarantee a rebound. The forward P/E ratio is 3.1676, which may seem attractive, but the company has reported negative net income in recent quarters, including a net loss of $4.75 million in Q3 2025. The main risk is the company's ongoing financial instability, as evidenced by a current ratio of 0.76, indicating potential liquidity issues. Overall, the combination of poor financial health and lack of positive catalysts makes SONM a sell at this time.

Valuation Metrics

The current forward P/E ratio for DNA X Inc (SONM) is 3.17, compared to its 5-year average forward P/E of 2.62.

Forward P/E

Fair
5Y Average P/E
2.62
Current P/E
3.17
Overvalued
12.22
Undervalued
-6.98

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
0.05
Current EV/EBITDA
0.00
Overvalued
4.10
Undervalued
-3.99

Forward P/S

Undervalued
5Y Average P/S
0.22
Current P/S
0.00
Overvalued
0.36
Undervalued
0.09

Whales holding SONM

L

L1 Capital Pty. Limited

+ HoldingSONM

-1.87%

3M Return

SONM FAQ — answered by Alphio AI

DNA X, Inc., formerly Sonim Technologies, Inc., is a digital asset management platform, building on the digital asset trading platform. The Company operates an artificial intelligence (AI) and crypto trading platform designed to automate trading strategies using machine learning technologies. It provides a digital asset trading platform that allows users to trade or swap cryptocurrencies for other cryptocurrencies or cash equivalent currencies. The Company’s DNA X trading website enables users to implement strategies to take advantage of fluctuations in relative values of cryptocurrency pairs. The platform allows users to set up automated trading strategies, monitor other traders’ trading strategies in real time, and simulate trades. The Company generates revenue from trading commissions based on the value of trades executed on its platform. It serves individual investors from around the world and supports its operations through subsidiaries located in China, Germany, and Hong Kong. It operates in the Technology sector (TELEPHONE & TELEGRAPH APPARATUS industry).

Sonim Technologies Inc (SONM) is not a good buy right now due to its significant financial losses and poor performance indicators. The current price is $3.08, and the stock has a 1-year change of -72.92%, indicating a substantial decline in value. Additionally, the RSI is at 30.545, suggesting that the stock is oversold, but this does not guarantee a rebound. The forward P/E ratio is 3.1676, which may seem attractive, but the company has reported negative net income in recent quarters, including a net loss of $4.75 million in Q3 2025. The main risk is the company's ongoing financial instability, as evidenced by a current ratio of 0.76, indicating potential liquidity issues. Overall, the combination of poor financial health and lack of positive catalysts makes SONM a sell at this time.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading